Tag Archives: Amy Judd

XoMotion, an exoskeleton developed in Canada causes commotion

I first stumbled across these researchers in 2016 when their project was known as “Wearable Lower Limb Anthropomorphic Exoskeleton (WLLAE).” In my January 20, 2016 posting, “#BCTECH: being at the Summit (Jan. 18-19, 2016),” an event put on by the province of British Columbia (BC, Canada) and the BC Innovation Council (BCIC), I visited a number of booths and talks at the #BC TECH Summit and had this to say about WLLAE,

“The Wearable Lower Limb Anthropomorphic Exoskeleton (WLLAE) – a lightweight, battery-operated and ergonomic robotic system to help those with mobility issues improve their lives. The exoskeleton features joints and links that correspond to those of a human body and sync with motion. SFU has designed, manufactured and tested a proof-of-concept prototype and the current version can mimic all the motions of hip joints.” The researchers (Siamak Arzanpour and Edward Park) pointed out that the ability to mimic all the motions of the hip is a big difference between their system and others which only allow the leg to move forward or back. They rushed the last couple of months to get this system ready for the Summit. In fact, they received their patent for the system the night before (Jan. 17, 2016) the Summit opened.

Unfortunately, there aren’t any pictures of WLLAE yet and the proof-of-concept version may differ significantly from the final version. This system could be used to help people regain movement (paralysis/frail seniors) and I believe there’s a possibility it could be used to enhance human performance (soldiers/athletes). The researchers still have some significant hoops to jump before getting to the human clinical trial stage. They need to refine their apparatus, ensure that it can be safely operated, and further develop the interface between human and machine. I believe WLLAE is considered a neuroprosthetic device. While it’s not a fake leg or arm, it enables movement (prosthetic) and it operates on brain waves (neuro). It’s a very exciting area of research, consequently, there’s a lot of international competition. [ETA January 3, 2024: I’m pretty sure I got the neuroprosthetic part wrong]

Time moved on and there was a name change and then there was this November 10, 2023 article by Jeremy Hainsworth for the Vancouver is Awesome website,

Vancouver-based fashion designer Chloe Angus thought she’d be in a wheelchair for the rest of her life after being diagnosed with an inoperable benign tumour in her spinal cord in 2015, resulting in permanent loss of mobility in her legs.

Now, however, she’s been using a state-of-the-art robotic exoskeleton known as XoMotion that can help physically disabled people self-balance, walk, sidestep, climb stairs and crouch.

“The first time I walked with the exoskeleton was a jaw-dropping experience,” said Angus. “After all these years, the exoskeleton let me stand up and walk on my own without falling. I felt like myself again.”

She added the exoskeleton has the potential to completely change the world for people with motion disabilities.

XoMotion is the result of a decade of research and the product of a Simon Fraser University spinoff company, Human in Motion Robotics (HMR) Inc. It’s the brainchild of professors Siamak Arzanpour and Edward Park.

Arzanpour and Park, both researchers in the Burnaby-based university’s School of Mechatronic Systems Engineering, began work on the device in 2014. They had a vision to enhance exoskeleton technology and empower individuals with mobility challenges to have more options for movement.

“We felt that there was an immediate need to help people with motion disabilities to walk again, with a full range of motion. At the time, exoskeletons could only walk forward. That was the only motion possible,” Arzanpour said.

A November 15, 2023 article (with an embedded video) by Amy Judd & Alissa Thibault for Global News (television) highlights Alexander’s story,

SFU professors Siamak Arzanpour and Edward Park wanted to help people with motion disabilities to walk freely, naturally and independently.

The exoskeleton [XoMotion] is now the most advanced of its kind in the world.

Chloe Angus, who lost her mobility in her legs in 2015, now works for the team.

She said the exoskeleton makes her feel like herself again.

She was diagnosed with an inoperable benign tumor in her spinal cord in 2015 which resulted in a sudden and permanent loss of mobility in her legs. At the time, doctors told Angus that she would need a wheelchair to move for the rest of her life.

Now she is part of the project and defying all odds.

“After all these years, the exoskeleton let me stand up and walk on my own without falling. I felt like myself again.”

There’s a bit more information in the November 8, 2023 Simon Fraser University (SFU) news release (which has the same embedded video as the Global News article) by Ray Sharma,

The state-of-the-art robotic exoskeleton known as XoMotion is the result of a decade of research and the product of an SFU spin off company, Human in Motion Robotics (HMR) Inc. The company has recently garnered millions in investment, an overseas partnership and a suite of new offices in Vancouver.

XoMotion allows individuals with mobility challenges to stand up and walk on their own, without additional support. When in use, XoMotion maintains its stability and simultaneously encompasses all the ranges of motion and degrees of freedom needed for users to self-balance, walk, sidestep, climb stairs, crouch, and more. 

Sensors within the lower-limb exoskeleton mimic the human body’s sense of logic to identify structures along the path, and in-turn, generate a fully balanced motion.

SFU professors Siamak Arzanpour and Edward Park, both researchers in the School of Mechatronic Systems Engineering, began work on the device in 2014 with a vision to enhance exoskeleton technology and empower individuals with mobility challenges to have more options for movement. 

“We felt that there was an immediate need to help people with motion disabilities to walk again, with a full range of motion. At the time, exoskeletons could only walk forward. That was the only motion possible,” says Arzanpour. 

The SFU professors, who first met in 2001 as graduate students at the University of Toronto, co-founded HMR in 2016, bringing together a group of students, end-users, therapists, and organizations to build upon the exoskeleton. Currently, 70 per cent of HMR employees are SFU graduates. 

In recent years, HMR has garnered multiple streams of investment, including a contract with Innovative Solutions Canada, and $10 million in funding during their Series A round in May, including an $8 million investment and strategic partnership from Beno TNR, a prominent Korean technology investment firm.

I decided to bring the embedded video here, it runs a little over 2 mins.,

You can find the Human in Robotics (HMR) website here.

A Vancouver (Canada) connection to the Pfizer COVID-19 vaccine

Canada’s NanoMedicines Innovation Network (NMIN) must have been excited over the COVID-19 vaccine news (Pfizer Nov. 9, 2020 news release) since it’s a Canadian company (Acuitas Therapeutics) that is providing the means of delivering the vaccine once it enters the body.

Here’s the company’s president and CEO [chief executive officer], Dr. Thomas Madden explaining his company’s delivery system (from Acuitas’ news and events webpage),

For anyone who might find a textual description about the vaccine helpful, I have a Nov. 9, 2020 article by Adele Peters for Fast Company,

… a handful of small biotech companies began scrambling to develop vaccines using an as-yet-unproven technology platform that relies on something called messenger RNA [ribonucleic acid], usually shortened to mRNA …

Like other vaccines, mRNA vaccines work by training the immune system to recognize a threat like a virus and begin producing antibodies to protect itself. But while traditional vaccines often use inactivated doses of the organisms that cause disease, mRNA vaccines are designed to make the body produce those proteins itself. Messenger RNA—a molecule that contains instructions for cells to make DNA—is injected into cells. In the case of COVID-19, mRNA vaccines provide instructions for cells to start producing the “spike” protein of the new coronavirus, the protein that helps the virus get into cells. On its own, the spike protein isn’t harmful. But it triggers the immune system to begin a defensive response. As Bill Gates, who has supported companies like Moderna and BioNTech through the Gates Foundation, has described it, “you essentially turn your body into its own manufacturing unit.”

Amy Judd’s Nov. 9, 2020 article for Global news online explains (or you can just take another look at the video to refresh your memory) how the Acuitas technology fits into the vaccine picture,

Vancouver-based Acuitas Therapeutics, a biotechnology company, is playing a key role through a technology known as lipid nanoparticles, which deliver messenger RNA into cells.

“The technology we provide to our partners is lipid nanoparticles and BioNTech and Pfizer are developing a vaccine that’s using a messenger RNA that tells our cells how to make a protein that’s actually found in the COVID-19 virus,” Dr. Thomas Madden, president and CEO of Acuitas Therapeutics, told Global News Monday [Nov. 9, 2020].

“But the messenger RNA can’t work by itself, it needs a delivery technology to protect this after it’s administered and then to carry it into the cells where it can be expressed and give rise to an immune response.”

Madden said they like to think of the lipid nanoparticles as protective wrapping around a fragile glass ornament [emphasis mine] being shipped to your house online. That protective wrapping would then make sure the ornament made it to your house, through your front door, then unwrap itself and leave in your hallway, ready for you to come and grab it when you came home.

Acuitas Therapeutics employs 29 people and Madden said he believes everyone is feeling very proud of their work.

“Not many people are aware of the history of this technology and the fact that it originated in Vancouver,” he added.

“Dr. Pieter Cullis was one of the key scientists who brought together a team to develop this technology many, many years ago. UBC and Vancouver and companies associated with those scientists have been at the global centre of this technology for many years now.

“I think we’ve been looking for a light at the end of the tunnel for quite some time. I think everybody has been hoping that a vaccine would be able to provide the protection we need to move out of our current situation and I think this is now a confirmation that this hope wasn’t misplaced.”

Nanomedicine in Vancouver

For anyone who’s curious about the Canadian nanomedicine scene, you can find out more about it on Canada’s NanoMedicines Innovation Network (NMIN) website. They recently held a virtual event (Vancouver Nanomedicine Day) on Sept. 17, 2020 (see my Sept. 11, 2020 posting for details), which featured a presentation about Aquitas’ technology.

Happily, the organizers have posted videos for most of the sessions. Dr. Ying Tam of Acuitas made this presentation (about 22 mins. running time) “A Novel Vaccine Approach Using Messenger RNA‐Lipid Nanoparticles: Preclinical and Clinical Perspectives.” If you’re interested in that video or any of the others go to the NanoMedicines Innovation Network’s Nanomedicine Day 2020 webpage.

Acuitas Therapeutics can be found here.